Latest Operating Expenses News

Bendigo Bank reported a slight dip in cash earnings for the half year ending December 2024, despite robust growth in customer deposits and ongoing investments in its transformation program.

Bendigo and Adelaide Bank reported a modest dip in cash earnings for the half year ended December 2024, offset by strong residential lending growth and a maintained fully franked dividend. The bank’s strategic investments and digital transformation efforts continue amid margin compression and rising expenses.

Audinate’s 1H25 results surpassed market expectations despite a 29% drop in gross profit, driven by a strategic shift towards higher-margin software products and a robust cash position.

Audinate Group Limited's half-year results reveal a sharp 38.4% revenue decline and a $2.2 million net loss, driven by reduced chip demand as customers clear inventory. Yet, growth in OEM partnerships hints at potential recovery.

Burgundy Diamond Mines has secured a novel diesel fuel offtake agreement with Macquarie Bank, easing seasonal cash flow pressures and potentially setting a precedent for multi-year collaboration.

GPT Management Holdings Limited reported a substantial net loss of $40.6 million for the year ended December 31, 2024, despite a 31.7% increase in total revenues to $340 million. No dividends were declared, signaling a cautious outlook amid challenging conditions.

Westpac's 1Q25 results reveal a solid financial footing with a $1.7 billion net profit, strong capital ratios, and resilient credit quality despite a modest revenue dip.

Contact Energy's January 2025 report reveals steady mass market electricity sales and improved netback prices, despite a notable decline in total electricity generation and national demand.

Forbidden Foods Limited has raised $1 million to boost inventory for its Blue Dinosaur and Oat Milk Goodness brands, following a remarkable 104% jump in quarterly sales.

GQG Partners delivered robust full-year 2024 results, marked by a 26.9% increase in funds under management and nearly 47% growth in net revenue, underpinned by strong investment performance and strategic initiatives including Private Capital Solutions and a new Abu Dhabi office.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.